Global Oncology/Anti-Cancer Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug Class;
Chemotherapy, Targeted Therapy Immunotherapy (Biologic Therapy), and Hormonal Therapy.By Indication;
Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Other Cancers.By Therapeutic Modalities;
Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, and Others.By Cancer Types;
Blood Cancer (Leukaemia), Breast Cancer, Gastrointestinal Cancer, Respiratory/Lung Cancer, Skin Cancer, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Oncology/Anti-Cancer Drugs Market (USD Million), 2021 - 2031
In the year 2024, the Global Oncology/Anti-Cancer Drugs Market was valued at USD 217,485.46 million. The size of this market is expected to increase to USD 349,234.13 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7%.
The global oncology and anti-cancer drugs market stands at the forefront of medical innovation, driven by groundbreaking research, technological advancements, and an ever-growing demand for effective treatments against cancer. With cancer continuing to pose a significant global health challenge, pharmaceutical companies, research institutions, and healthcare providers are tirelessly working to develop novel therapies and enhance existing ones. This dynamic landscape is characterized by a diverse array of drugs targeting various types and stages of cancer, offering hope to millions of patients worldwide.
The oncology market has witnessed remarkable growth, propelled by factors such as increasing cancer prevalence, aging populations, and expanding access to healthcare services in emerging economies. Innovative treatments such as immunotherapies, targeted therapies, and precision medicine have revolutionized cancer care, offering more personalized and effective options for patients. Moreover, the advent of biosimilars and the rise of combination therapies have further enriched the treatment armamentarium, fostering competition and driving market expansion.
The oncology and anti-cancer drugs market also faces challenges, including stringent regulatory requirements, pricing pressures, and the emergence of resistance to existing therapies. Nevertheless, ongoing research efforts, collaborations across academia and industry, and advances in areas like genomics and artificial intelligence continue to fuel optimism for the future of cancer treatment. As the quest for better outcomes and improved quality of life for cancer patients persists, the global oncology market remains a beacon of innovation and hope in the fight against one of humanity's most formidable adversaries.
Global Oncology/Anti-Cancer Drugs Market Recent Developments
- February 2024, AbbVie Inc. acquired ImmunoGen, a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer, to strengthen the company’s position in the oncology segment.
- February 2024, Novartis AG acquired MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology, to strengthen its oncology pipeline.
- January 2024, AbbVie Inc. collaborated with Umoja Biopharma, a company focused on immunotherapy by reprogramming T cells in vivo to target cancer cells to develop novel In-Situ CAR-T cell therapies.
Segment Analysis
The Global Oncology/Anti-Cancer Drugs Market is segmented by drug class, indication, therapeutic modalities, and cancer types, each offering unique insights into market dynamics. By drug class, the market includes chemotherapy, targeted therapy, immunotherapy, and hormone therapy. Targeted therapy dominates due to its precision in attacking cancer cells while sparing healthy ones, supported by advancements in molecular profiling and biomarker identification. Immunotherapy, including immune checkpoint inhibitors and CAR-T cell therapies, is experiencing rapid growth owing to its transformative impact on treating aggressive and metastatic cancers. Hormone therapy remains critical for hormone-dependent cancers such as breast and prostate cancer, while chemotherapy, though declining in preference, remains essential for certain cancer types and low-resource settings.
By indication, the market addresses solid tumors, hematologic malignancies, and supportive care. Solid tumors, encompassing cancers like lung, breast, and colorectal, account for the largest share, driven by their high global incidence and the availability of diverse treatment options. Hematologic malignancies, including leukemia, lymphoma, and myeloma, are gaining attention due to advancements in biologics and personalized medicine. Supportive care drugs, designed to manage treatment side effects, are an integral component of oncology care, enhancing patient quality of life during therapy.
Segmentation by therapeutic modalities includes small molecules, biologics, and combination therapies. Small molecules are widely used for their ability to penetrate cells and disrupt cancer cell pathways, while biologics, such as monoclonal antibodies and antibody-drug conjugates, are gaining ground for their high specificity and efficacy. Combination therapies, which integrate multiple modalities, are becoming standard practice to overcome drug resistance and improve treatment outcomes, especially in complex cancers.
Cancer type segmentation spans lung cancer, breast cancer, colorectal cancer, prostate cancer, blood cancers, and others. Lung cancer leads due to its high prevalence and increasing adoption of targeted and immunotherapies. Breast cancer follows, bolstered by advancements in hormone receptor-targeted drugs and HER2 inhibitors. Colorectal cancer benefits from novel targeted agents and immunotherapies, while prostate cancer sees growth through innovative hormone therapies and radiopharmaceuticals. Blood cancers, particularly leukemia and lymphoma, are witnessing breakthroughs with CAR-T cell therapies and biologics.
Together, these segments underscore the market's rapid evolution driven by technological advancements, growing cancer awareness, and the increasing adoption of personalized and precision medicine. Rising investments in R&D and supportive regulatory frameworks are further accelerating innovation and access in the oncology drugs market.
Global Oncology/Anti-Cancer Drugs Market Analysis
In this report, the Global Oncology/Anti-Cancer Drugs Market has been segmented by Drug Class, Indication, Therapeutic Modalities, Cancer Types, and Geography.
Global Oncology/Anti-Cancer Drugs Market, Segmentation by Drug Class
The Global Oncology/Anti-Cancer Drugs Market has been segmented by Drug Class into Chemotherapy, Targeted Therapy Immunotherapy (Biologic Therapy), and Hormonal Therapy.
Chemotherapy, once the cornerstone of cancer treatment, remains essential for its broad-spectrum efficacy in killing rapidly dividing cancer cells, particularly in aggressive or advanced-stage cancers. However, its declining preference in some regions is attributed to severe side effects and the rise of more targeted and personalized treatment options.
Targeted therapy has become a dominant segment, driven by its precision in attacking specific cancer cell pathways while minimizing damage to healthy tissues. The development of molecular profiling and biomarker identification has fueled the adoption of targeted drugs, especially in cancers like lung, breast, and colorectal, where specific genetic mutations can be addressed effectively.
Immunotherapy, or biologic therapy, is witnessing exponential growth as it revolutionizes cancer care with innovative approaches like immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines. These therapies boost the body's immune system to recognize and destroy cancer cells, offering significant survival benefits in challenging cases such as metastatic melanoma and certain hematologic malignancies. Lastly, hormonal therapy remains a cornerstone for treating hormone-sensitive cancers such as breast and prostate cancer, focusing on disrupting hormonal signals that fuel cancer growth. Collectively, these drug classes highlight the ongoing shift towards precision medicine and patient-centric oncology care.
Global Oncology/Anti-Cancer Drugs Market, Segmentation by Indication
The Global Oncology/Anti-Cancer Drugs Market has been segmented by Indication into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Other Cancers.
Lung cancer leads the market, driven by its high global prevalence and advancements in targeted therapies and immunotherapies, particularly for non-small cell lung cancer (NSCLC). Breast cancer also holds a significant share, fueled by increased awareness, routine screening programs, and the availability of advanced hormone therapies, HER2-targeted drugs, and CDK4/6 inhibitors.
Colorectal cancer represents a major segment, benefiting from the integration of immunotherapies and targeted agents such as EGFR and VEGF inhibitors in treatment regimens. Prostate cancer remains a critical focus area, with innovations in androgen deprivation therapies and novel radiopharmaceuticals enhancing treatment outcomes. Liver cancer is gaining attention due to rising incidence rates, particularly in regions with high hepatitis prevalence, with immunotherapy and kinase inhibitors driving advancements in care.
Stomach and esophagus cancers, though less common in developed countries, account for a notable share in the global market due to their prevalence in Asia-Pacific regions. Targeted therapies, such as HER2 inhibitors, are increasingly adopted in these cancers. Cervical cancer benefits from advancements in checkpoint inhibitors and immune-oncology agents, offering new hope for patients with advanced or recurrent disease. Kidney and bladder cancers are witnessing significant innovation, particularly with immune checkpoint inhibitors and VEGF-targeted therapies. The "other cancers" category encompasses rarer cancers like pancreatic, ovarian, and hematologic malignancies, which are gaining attention due to growing R&D efforts and the development of personalized medicines. Together, these indications showcase the market's extensive reach and focus on addressing the varied and complex needs of cancer treatment worldwide.
Global Oncology/Anti-Cancer Drugs Market, Segmentation by Therapeutic Modalities
The Global Oncology/Anti-Cancer Drugs Market has been segmented by Therapeutic Modalities into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, and Others.
The Global Oncology/Anti-Cancer Drugs Market is undergoing a profound transformation, driven by a diverse array of therapeutic modalities aimed at combating cancer from multiple angles. Chemotherapy, a stalwart in cancer treatment, continues to play a crucial role by targeting rapidly dividing cancer cells throughout the body. Despite its efficacy, chemotherapy is often associated with significant side effects, spurring the development of more targeted and precise therapies.
Targeted therapy represents a paradigm shift in cancer treatment, focusing on specific molecular alterations driving tumor growth and progression. By precisely targeting these aberrant pathways, targeted therapies offer the potential for enhanced efficacy and reduced toxicity compared to conventional chemotherapy. This approach has yielded remarkable success in treating certain cancers, paving the way for further innovations in precision medicine.
Immunotherapy, also known as biologic therapy, has emerged as a game-changer in the oncology landscape, harnessing the body's immune system to identify and destroy cancer cells. Immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are among the innovative immunotherapeutic approaches revolutionizing cancer treatment. By unleashing the power of the immune system, immunotherapy has demonstrated remarkable efficacy across a range of cancer types, heralding a new era in cancer care.
Global Oncology/Anti-Cancer Drugs Market, Segmentation by Cancer Types
The Global Oncology/Anti-Cancer Drugs Market has been segmented by Cancer Types into Blood Cancer(Leukaemia), Breast Cancer, Gastrointestinal Cancer, Respiratory/Lung Cancer, Skin Cancer, and Others.
The segmentation of the Global Oncology/Anti-Cancer Drugs Market by Cancer Types reflects the diverse landscape of malignancies and the tailored approaches required for effective treatment. Blood cancers, encompassing leukemia, lymphoma, and myeloma, present unique challenges due to their origin in the blood-forming tissues and immune system. Treatment options for blood cancers often involve chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation, highlighting the need for comprehensive and multidisciplinary care.
Breast cancer stands as one of the most prevalent malignancies globally, with various subtypes necessitating personalized treatment approaches. Hormonal therapy, targeted therapy, chemotherapy, and immunotherapy are among the modalities employed in the management of breast cancer, underscoring the importance of early detection and tailored treatment strategies.
Gastrointestinal cancers, including colorectal, pancreatic, and liver cancers, represent a significant burden on global health systems due to their high incidence and mortality rates. Treatment options for gastrointestinal cancers vary depending on factors such as tumor stage, location, and molecular characteristics. Surgical resection, chemotherapy, targeted therapy, and immunotherapy are integral components of the treatment paradigm, highlighting the need for a multidisciplinary approach to optimize patient outcomes.
Global Oncology/Anti-Cancer Drugs Market, Segmentation by Geography
In this report, the Global Oncology/Anti-Cancer Drugs Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Oncology/Anti-Cancer Drugs Market Share (%), by Geographical Region, 2024
The Global Oncology/Anti-Cancer Drugs Market, geographical segmentation into five regions provides valuable insights into regional trends, challenges, and opportunities shaping the landscape of cancer care worldwide. North America, comprising the United States and Canada, stands as a major hub for oncology research, innovation, and market growth. With a robust healthcare infrastructure and substantial investments in cancer research and development, North America leads the way in introducing novel therapies and advancing precision medicine approaches.
Europe, encompassing a diverse array of healthcare systems across countries such as the United Kingdom, Germany, and France, represents another key market for oncology drugs. European nations prioritize healthcare accessibility and affordability while fostering collaboration between academia, industry, and regulatory bodies. This collaborative ecosystem facilitates the introduction of innovative cancer treatments and ensures patients have access to the latest advancements in oncology care.
The Asia Pacific region, including countries like China, Japan, and India, holds immense potential for the growth of the oncology drugs market. Rapidly expanding economies, increasing healthcare expenditure, and a rising prevalence of cancer contribute to the region's significance in the global oncology landscape. Moreover, initiatives aimed at improving cancer awareness, early detection, and treatment accessibility are driving market expansion across the Asia Pacific, albeit with unique challenges related to regulatory frameworks, pricing, and reimbursement policies.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Oncology/Anti-Cancer Drugs Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Research Innovation
- Aging Population
- Demand Surge
-
Personalized Medicine - Personalized medicine, also known as precision medicine, represents a revolutionary approach to healthcare that tailors medical treatment and interventions to individual characteristics, such as genetic makeup, lifestyle, and environmental factors. By leveraging advances in genomics, molecular diagnostics, and data analytics, personalized medicine aims to optimize therapeutic outcomes while minimizing adverse effects. This patient-centric approach enables healthcare providers to make more informed decisions regarding treatment selection, dosage, and monitoring, leading to improved efficacy and safety.
One of the key drivers behind the adoption of personalized medicine is the growing recognition of the heterogeneity of diseases, including cancer. Traditional one-size-fits-all treatments often yield suboptimal results due to variations in patients' genetic profiles and disease characteristics. Personalized medicine seeks to address this challenge by identifying biomarkers and genetic signatures that can predict treatment response and guide therapy selection. By matching patients with the most appropriate treatments based on their individual molecular profiles, personalized medicine holds the promise of transforming the paradigm of cancer care, offering hope for better outcomes and quality of life.
Despite its transformative potential, the widespread implementation of personalized medicine faces several challenges, including regulatory complexities, reimbursement issues, and data privacy concerns. Regulatory agencies are tasked with evaluating the safety, efficacy, and validity of companion diagnostics used in conjunction with targeted therapies, requiring robust evidence to support their clinical utility. Moreover, the integration of genomic data into routine clinical practice necessitates significant investments in infrastructure, workforce training, and data interoperability. However, ongoing efforts to address these challenges, coupled with advances in technology and collaborative initiatives, are paving the way for the broader adoption of personalized medicine, heralding a new era of precision oncology.
Restraints:
- High Development Costs
- Patent Expirations
-
Pricing Pressures - Pricing pressures in the oncology and anti-cancer drugs market exert significant influence on healthcare systems, pharmaceutical companies, and patients alike. As the cost of cancer care continues to rise globally, payers, including governments, insurers, and healthcare providers, face mounting financial burdens in ensuring access to essential treatments while maintaining fiscal sustainability. Pharmaceutical companies, on the other hand, confront intense scrutiny and negotiation over drug pricing, driven by concerns over affordability, value, and cost-effectiveness.
One of the primary drivers of pricing pressures in the oncology drugs market is the high cost of research and development (R&D) coupled with the uncertain returns on investment. Developing novel cancer therapies entails substantial investments in preclinical studies, clinical trials, regulatory approvals, and post-marketing surveillance, often spanning over a decade and costing billions of dollars. Consequently, pharmaceutical companies seek to recoup these investments by pricing drugs at levels that reflect their perceived value and market demand, leading to contentious debates over affordability and access.
The emergence of biosimilars and generic competition exerts downward pressure on drug prices, particularly for blockbuster oncology drugs nearing patent expiration. Biosimilars, which are biologic products that are highly similar to and have no clinically meaningful differences from an existing approved reference product, offer cost-saving opportunities for healthcare systems and payers. However, their entry into the market can erode market share and revenue streams for originator companies, prompting strategic pricing adjustments and competitive pricing strategies.
The implications of pricing pressures extend beyond pharmaceutical companies and payers to patients who may face financial toxicity as a result of high out-of-pocket expenses for cancer treatments. Affordability challenges can lead to treatment non-adherence, delayed care-seeking behavior, and disparities in access to innovative therapies, exacerbating health outcomes and socioeconomic inequalities. Addressing pricing pressures in the oncology drugs market requires a multifaceted approach involving collaboration among stakeholders, innovative reimbursement models, and policy interventions aimed at balancing affordability with sustainability and equitable access to life-saving treatments.
Opportunities:
- Precision Medicine
- Immunotherapy Advancements
-
Biosimilars Growth - The growth of biosimilars in the oncology and anti-cancer drugs market represents a significant opportunity to enhance access to life-saving treatments while fostering competition and driving cost savings. Biosimilars are biologic products that are highly similar to and have no clinically meaningful differences from an approved reference biologic product. Unlike generic drugs, which are identical copies of small molecule drugs, biosimilars are complex molecules derived from living organisms, necessitating rigorous comparability assessments to demonstrate similarity in terms of efficacy, safety, and quality.
The oncology biosimilars market has witnessed rapid expansion, fueled by factors such as patent expirations of originator biologics, increasing demand for cost-effective cancer therapies, and supportive regulatory frameworks. Oncology represents a particularly attractive therapeutic area for biosimilar development, given the high cost of biologic cancer treatments and the potential for substantial cost savings with biosimilars. By offering more affordable alternatives to expensive biologics, biosimilars hold the promise of expanding treatment options, improving patient access, and alleviating financial burdens on healthcare systems and payers.
The growth of biosimilars in oncology is not without challenges. Key obstacles include regulatory complexities, market acceptance, physician and patient education, and manufacturing scalability. Regulatory agencies require comprehensive evidence demonstrating biosimilarity to the reference product through extensive analytical, preclinical, and clinical comparability studies. Market acceptance and adoption may vary depending on factors such as physician familiarity, confidence in biosimilar efficacy and safety, and healthcare system incentives. Moreover, manufacturing biosimilars involves sophisticated bioprocesses and quality control measures to ensure consistency and reproducibility, which can pose challenges for manufacturers.
Despite these challenges, the oncology biosimilars market is poised for continued growth and evolution, driven by ongoing patent expirations of biologic drugs, increasing acceptance and adoption among healthcare providers and payers, and efforts to streamline regulatory pathways and foster competition. As biosimilars continue to gain traction in the oncology landscape, they have the potential to enhance treatment access, improve affordability, and contribute to more sustainable and equitable cancer care globally.
Competitive Landscape Analysis
Key players in Global Oncology/Anti-Cancer Drugs Market include:
- Amgen Inc.
- AstraZeneca PLC.
- Roche Diagnostics
- GlaxoSmithKline PLC
- Merck & Company
- Novartis AG
- AbbVie Inc.
- Sanofi
- EIMC United Pharmaceuticals (EUP)
- Actavis plc
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Indication
- Market Snapshot, By Therapeutic Modalities
- Market Snapshot, By Cancer Types
- Market Snapshot, By Region
- Market Snapshot, By Drug Class
- Global Oncology/Anti-Cancer Drugs Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Research Innovation
- Aging Population
- Demand Surge
- Personalized Medicine
- Restraints
- High Development Costs
- Patent Expirations
- Pricing Pressures
- Opportunities
- Precision Medicine
- Immunotherapy Advancements
- Biosimilars Growth
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Oncology/Anti-Cancer Drugs Market, By Drug Class, 2021 - 2031 (USD Million)
- Chemotherapy,
- Targeted Therapy Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Global Oncology/Anti-Cancer Drugs Market, By Indication, 2021 - 2031 (USD Million)
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Esophagus Cancer
- Cervical Cancer,
- Kidney Cancer
- Bladder Cancer
- Other Cancers
- Global Oncology/Anti-Cancer Drugs Market, By Therapeutic Modalities, 2021 - 2031 (USD Million)
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Others
- Global Oncology/Anti-Cancer Drugs Market, By Cancer Types, 2021 - 2031 (USD Million)
- Blood Cancer (Leukaemia)
- Breast Cancer
- Gastrointestinal Cancer
- Respiratory/Lung Cancer
- Skin Cancer
- Others
- Global Oncology/Anti-Cancer Drugs Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Oncology/Anti-Cancer Drugs Market, By Drug Class, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Amgen Inc.
- AstraZeneca PLC.
- Roche Diagnostics
- GlaxoSmithKline PLC
- Merck & Company
- Novartis AG
- AbbVie Inc.
- Sanofi
- EIMC United Pharmaceuticals (EUP)
- Actavis plc
- Company Profiles
- Analyst Views
- Future Outlook of the Market